Top

Journal of Diabetes & Metabolic Disorders

Published in:

05-11-2022 | Diabetic Neuropathy | Research article

Association between P300 parameters and cognitive function in people with diabetic neuropathy

Authors: Sarah Parveen, Majumi M. Noohu

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2023

Abstract

Purpose

The purpose of this study was to investigate the association between event-related potential (ERP) P300 with cognitive function in people with diabetic peripheral neuropathy (DPN).

Methods

We performed a cross-sectional analysis of 19 type 2 diabetes mellitus (T2DM) patients, aged 18 and older with DPN. The participants were assessed for neuropathy, cognitive function, & dual-task performance. DPN was examined via the administration of diabetic neuropathy symptom score (DNSS) and vibration perception threshold (VPT). Cognitive dysfunction was evaluated using Mini-mental state examination (MMSE), trail making test-B (TMT-B), and ERP P300 wave latency & amplitude. For assessing dual-task performance, the dual-task cost (DTC) was calculated using the timed-up and go (TUG) test and TUG with dual task (TUG-DT).

Results

P300 latency was linearly related to TMT-B (R = 0.31, p = 0.01) and DTC (R = 0.22, p = 0.04). A similar trend was observed in TMT-B (R = 0.13, p = 0.04) & DTC (R =0 .67, p = 0.001) with respect to P300 amplitude. MMSE did not relate with P300 latency (R = 0.14, p = 0.58) & amplitude (R = 0.63, p = .44).

Conclusion

P300 latency and amplitude are associated with cognitive function and DTC of individuals with DPN.

Xiling L, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790. doi:https://doi.org/10.1038/s41598-020-71908-9.CrossRef

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9. Diabetes Res Clin Pract. 2019;157:107843. doi:https://doi.org/10.1016/j.diabres.2019.107843.CrossRefPubMed

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 2014;5(6):714–21. doi:https://doi.org/10.1111/jdi.12223.CrossRefPubMedPubMedCentral

Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93. doi:https://doi.org/10.2337/dc10-1303.CrossRefPubMedPubMedCentral

Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diab Rep. 2019;19(10):86. doi:https://doi.org/10.1007/s11892-019-1212-8.CrossRefPubMedPubMedCentral

Boulton AJ. Diabetic neuropathy and foot complications. Handb Clin Neurol. 2014;126:97–107. doi:https://doi.org/10.1016/b978-0-444-53480-4.00008-4.CrossRefPubMed

Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am. 2013;97(5):791–805. doi:https://doi.org/10.1016/j.mcna.2013.03.008.CrossRefPubMed

Hewston P, Deshpande N. Falls and Balance Impairments in Older Adults with Type 2 Diabetes: Thinking Beyond Diabetic Peripheral Neuropathy. Can J Diabetes. 2016;40(1):6–9. doi:https://doi.org/10.1016/j.jcjd.2015.08.005.CrossRefPubMed

Nooyens ACJ, Baan CA, Spijkerman AMW, Monique Verschuren WM. Type 2 diabetes and cognitive decline in middle-aged men and women: The doetinchem cohort study. Diabetes Care. 2010;33(9):1964–9. doi:https://doi.org/10.2337/dc09-2038.CrossRefPubMedPubMedCentral

10.

Elsharkawy RE, Azim GSA, Osman MA, Maghraby HM, Mohamed RA, Abdelsalam EM, et al. Peripheral polyneuropathy and cognitive impairment in Type II diabetes mellitus. Neuropsychiatr Dis Treat. 2021;17:627–35. doi:https://doi.org/10.2147/NDT.S284308.CrossRefPubMedPubMedCentral

11.

Rawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014;161(11):785–93. doi:https://doi.org/10.7326/m14-0737.CrossRefPubMedPubMedCentral

12.

Wrighten SA, Piroli GG, Grillo CA, Reagan LP. A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta. 2009;1792(5):444–53. doi:https://doi.org/10.1016/j.bbadis.2008.10.013.CrossRefPubMed

13.

Alosco ML, Gunstad J. The negative effects of obesity and poor glycemic control on cognitive function: a proposed model for possible mechanisms. Curr Diab Rep. 2014;14(6):495. doi:https://doi.org/10.1007/s11892-014-0495-z.CrossRefPubMedPubMedCentral

14.

Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604. doi:https://doi.org/10.1038/s41574-018-0048-7.CrossRefPubMedPubMedCentral

15.

Bilgin S, Kurtkulagi O, Atak Tel BM, Duman TT, Kahveci G, Khalid A, et al. Does C-reactive protein to serum Albumin Ratio correlate with diabEtic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study. Prim Care Diabetes. 2021;15(6):1071–4. doi:https://doi.org/10.1016/j.pcd.2021.08.015.CrossRefPubMed

16.

Kocak MZ, Aktas G, Atak BM, Duman TT, Yis OM, Erkus E, et al. Is Neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus? Eur J Clin Invest. 2020;50(3):e13206. doi:https://doi.org/10.1111/eci.13206.CrossRefPubMed

17.

Kocak MZ, Aktas G, Duman TT, Atak BM, Kurtkulagi O, Tekce H, et al. Monocyte lymphocyte ratio As a predictor of Diabetic Kidney Injury in type 2 Diabetes mellitus; The MADKID Study. J Diabetes Metab Disord. 2020;19(2):997–1002. doi:https://doi.org/10.1007/s40200-020-00595-0.CrossRefPubMedPubMedCentral

18.

Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23(5):1098–102. doi:https://doi.org/10.1080/13685538.2019.1678126.CrossRefPubMed

19.

Gao J, Wei B, Liu M, Hirsova P, Sehrawat TS, Cao S, et al. Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling. Hepatology. 2021;73(6):2468–83. doi:https://doi.org/10.1002/hep.31617.CrossRefPubMed

20.

Alvarenga Kde F, Duarte JL, Silva DP, Agostinho-Pesse RS, Negrato CA, Costa OA. Cognitive P300 potential in subjects with Diabetes Mellitus. Braz J Otorhinolaryngol. 2005;71(2):202–7. doi:https://doi.org/10.1016/s1808-8694(15)31311-2.CrossRefPubMed

21.

Tandon OP, Mahajan AS. Averaged evoked potentials: event related potentials (ERPs) and their applications. Indian J Physiol Pharmacol. 1999;43(4):425–34.PubMed

22.

Anandhalakshmi S, Rajkumar R, Arulmurugan K, Kumar J, Thirunavukarasu M. Study of Neurocognitive Function in Type 2 Diabetes Mellitus Patients Using P300 Event-Related Potential. Annals of Neurosciences. 2020:097275312096682. doi:https://doi.org/10.1177/0972753120966824.

23.

Licht R, Hömberg V. An introduction to methodology, psychophysiological significance and clinical applications. In: Colon EJ, Visser SL, editors. Evoked Potential Manual: A Practical Guide to Clinical Applications. Dordrecht: Springer Netherlands; 1990. pp. 327–53.CrossRef

24.

Goodin DS. Clinical utility of long latency ‘cognitive’ event-related potentials (P3): the pros. Electroencephalogr Clin Neurophysiol. 1990;76(1):2–5. doi:https://doi.org/10.1016/0013-4694(90)90051-k. discussion 1.CrossRefPubMed

25.

Goodin D, Desmedt J, Maurer K, Nuwer MR. IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994;91(1):18–20. doi:https://doi.org/10.1016/0013-4694(94)90014-0.CrossRefPubMed

26.

Polich J. Meta-analysis of P300 normative aging studies. Psychophysiology. 1996;33(4):334–53. doi:https://doi.org/10.1111/j.1469-8986.1996.tb01058.x.CrossRefPubMed

27.

Hazari MAH, Ram Reddy B, Uzma N, Santhosh Kumar B. Cognitive impairment in type 2 diabetes mellitus. Int J Diabetes Mellitus. 2015;3(1):19–24. doi:https://doi.org/10.1016/j.ijdm.2011.01.001.CrossRef

28.

Mancini M, Horak FB. The relevance of clinical balance assessment tools to differentiate balance deficits. Eur J Phys Rehabil Med. 2010;46(2):239–48.PubMed

29.

Tangen GG, Engedal K, Bergland A, Moger TA, Mengshoel AM. Relationships between balance and cognition in patients with subjective cognitive impairment, mild cognitive impairment, and Alzheimer disease. Phys Ther. 2014;94(8):1123–34. doi:https://doi.org/10.2522/ptj.20130298.CrossRefPubMed

30.

Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8. doi:https://doi.org/10.1111/j.1532-5415.1991.tb01616.x.CrossRefPubMed

31.

Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther. 2006;29(2):64–8. doi:https://doi.org/10.1519/00139143-200608000-00004.CrossRefPubMed

32.

Andreadou E, Mitrakou A, Constantinides V, Triantafyllou N. Auditory P300 event-related potentials in patients with type 2 diabetes mellitus. Journal of Diabetes Research & Clinical Metabolism. 2012;2012 1: 1 (29 March 2012). doi: https://doi.org/10.7243/2050-0866-1-1.

33.

Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–35. doi:https://doi.org/10.1111/j.1532-5415.1992.tb01992.x.CrossRefPubMed

34.

Lomholt RK, Jürgensen KS. [The mini-mental state examination in screening of cognitive dysfunction and dementia]. Ugeskr Laeger. 1998;160(50):7251–4.PubMed

35.

Kortte KB, Horner MD, Windham WK. The trail making test, part B: cognitive flexibility or ability to maintain set? Appl Neuropsychol. 2002;9(2):106–9. doi:https://doi.org/10.1207/s15324826an0902_5.CrossRefPubMed

36.

Bhatia T, Shriharsh V, Adlakha S, Bisht V, Garg K, Deshpande SN. The trail making test in India. Indian J Psychiatry. 2007;49(2):113–6. doi:https://doi.org/10.4103/0019-5545.33258.CrossRefPubMedPubMedCentral

37.

Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000;22(4):518–28. doi:https://doi.org/10.1076/1380-3395(200008)22:4;1-0;ft518.CrossRefPubMed

38.

Aseem A, Kauser H, Hussain ME. Non-action Video Game Training Ameliorates Cognitive Decline Associated with Sleep Disturbance. Sleep and Vigilance. 2018;2(2):157–65. doi:https://doi.org/10.1007/s41782-018-0050-0.CrossRef

39.

Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002;19(11):962–5. doi:https://doi.org/10.1046/j.1464-5491.2002.00819.x.CrossRefPubMed

40.

Rucker JL, Jernigan SD, McDowd JM, Kluding PM. Adults with diabetic peripheral neuropathy exhibit impairments in multitasking and other executive functions. J Neurol Phys Ther. 2014;38(2):104–10. doi:https://doi.org/10.1097/npt.0000000000000032.CrossRefPubMedPubMedCentral

41.

Ansai JH, Andrade LP, Rossi PG, Almeida ML, Carvalho Vale FA, Rebelatto JR. Association Between Gait and Dual Task With Cognitive Domains in Older People With Cognitive Impairment. J Mot Behav. 2018;50(4):409–15. doi:https://doi.org/10.1080/00222895.2017.1363702.CrossRefPubMed

42.

Maidan I, Fahoum F, Shustak S, Gazit E, Patashov D, Tchertov D, et al. Changes in event-related potentials during dual task walking in aging and Parkinson’s disease. Clin Neurophysiol. 2019;130(2):224–30. doi:https://doi.org/10.1016/j.clinph.2018.11.019.CrossRefPubMed

43.

Elsharkawy RE, Abdel Azim GS, Osman MA, Maghraby HM, Mohamed RA, Abdelsalam EM, et al. Peripheral Polyneuropathy and Cognitive Impairment in Type II Diabetes Mellitus. Neuropsychiatr Dis Treat. 2021;17:627–35. doi:https://doi.org/10.2147/ndt.s284308.CrossRefPubMedPubMedCentral

44.

Kumar S, C G, Edakkot S. Study of Dementia in Diabetic patients with particular reference to Cerad and Trail Making Test. International Journal of Scientific and Engineering Research. 2014;5.

45.

Polich J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol. 2007;118(10):2128–48. doi:https://doi.org/10.1016/j.clinph.2007.04.019.CrossRefPubMedPubMedCentral

46.

Menz HB, Lord SR, St George R, Fitzpatrick RC. Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy. Arch Phys Med Rehabil. 2004;85(2):245–52. doi:https://doi.org/10.1016/j.apmr.2003.06.015.CrossRefPubMed

47.

Abboud RJ, Rowley DI, Newton RW. Lower limb muscle dysfunction may contribute to foot ulceration in diabetic patients. Clin Biomech (Bristol Avon). 2000;15(1):37–45. doi:https://doi.org/10.1016/s0268-0033(99)00038-8.CrossRefPubMed

48.

Paul L, Ellis BM, Leese GP, McFadyen AK, McMurray B. The effect of a cognitive or motor task on gait parameters of diabetic patients, with and without neuropathy. Diabet Med. 2009;26(3):234–9. doi:https://doi.org/10.1111/j.1464-5491.2008.02655.x.CrossRefPubMed

49.

Courtemanche R, Teasdale N, Boucher P, Fleury M, Lajoie Y, Bard C. Gait problems in diabetic neuropathic patients. Arch Phys Med Rehabil. 1996;77(9):849–55. doi:https://doi.org/10.1016/s0003-9993(96)90269-5.CrossRefPubMed

50.

Leandri M, Campbell J, Molfetta L, Barbera C, Tabaton M. Relationship between balance and cognitive performance in older people. J Alzheimers Dis. 2015;45(3):705–7. doi:https://doi.org/10.3233/jad-142883.CrossRefPubMed

51.

Pichierri G, Wolf P, Murer K, de Bruin ED. Cognitive and cognitive-motor interventions affecting physical functioning: a systematic review. BMC Geriatr. 2011;11:29. doi:https://doi.org/10.1186/1471-2318-11-29.CrossRefPubMedPubMedCentral

52.

Popa T, Morris L, Hunt R, Deng Z-D, Horovitz S, Mente K, et al. Modulation of Resting Connectivity Between the Mesial Frontal Cortex and Basal Ganglia. Front Neurol. 2019;10. doi:https://doi.org/10.3389/fneur.2019.00587.

53.

Obeso I, Wilkinson L, Teo JT, Talelli P, Rothwell JC, Jahanshahi M. Theta burst magnetic stimulation over the pre-supplementary motor area improves motor inhibition. Brain Stimul. 2017;10(5):944–51. doi:https://doi.org/10.1016/j.brs.2017.05.008.CrossRefPubMed

54.

Påhlman U, Gutiérrez-Pérez C, Sävborg M, Knopp E, Tarkowski E. Cognitive function and improvement of balance after stroke in elderly people: the Gothenburg cognitive stroke study in the elderly. Disabil Rehabil. 2011;33(21–22):1952–62. doi:https://doi.org/10.3109/09638288.2011.553703.CrossRefPubMed

55.

Verlinden VJ, de Groot M, Cremers LG, van der Geest JN, Hofman A, Niessen WJ, et al. Tract-specific white matter microstructure and gait in humans. Neurobiol Aging. 2016;43:164–73. doi:https://doi.org/10.1016/j.neurobiolaging.2016.04.005.CrossRefPubMed

56.

Peters S, Eng JJ, Liu-Ambrose T, Borich MR, Dao E, Amanian A, et al. Brain activity associated with Dual-task performance of Ankle motor control during cognitive challenge. Brain Behav. 2019;9(8):e01349. doi:https://doi.org/10.1002/brb3.1349.CrossRefPubMedPubMedCentral

57.

Blumen HM, Holtzer R, Brown LL, Gazes Y, Verghese J. Behavioral and neural correlates of imagined walking and walking-while-talking in the elderly. Hum Brain Mapp. 2014;35(8):4090–104. doi:https://doi.org/10.1002/hbm.22461.CrossRefPubMedPubMedCentral

58.

Leone C, Feys P, Moumdjian L, D’Amico E, Zappia M, Patti F. Cognitive-motor dual-task interference: A systematic review of neural correlates. Neurosci Biobehav Rev. 2017;75:348–60. doi:https://doi.org/10.1016/j.neubiorev.2017.01.010.CrossRefPubMed

59.

Bachiller A, Romero S, Molina V, Alonso JF, Mañanas MA, Poza J, et al. Auditory P3a and P3b neural generators in schizophrenia: An adaptive sLORETA P300 localization approach. Schizophr Res. 2015;169(1–3):318–25. doi:https://doi.org/10.1016/j.schres.2015.09.028.CrossRefPubMed

60.

Wronka E, Kaiser J, Coenen AM. Neural generators of the auditory evoked potential components P3a and P3b. Acta Neurobiol Exp (Wars). 2012;72(1):51–64.PubMed

61.

Medeiros-Ward N, Watson JM, Strayer DL. On supertaskers and the neural basis of efficient multitasking. Psychon Bull Rev. 2015;22(3):876–83. doi:https://doi.org/10.3758/s13423-014-0713-3.CrossRefPubMed

62.

Tripathi S, Verghese J, Blumen HM. Gray matter volume covariance networks associated with dual-task cost during walking-while-talking. Hum Brain Mapp. 2019;40(7):2229–40. doi:https://doi.org/10.1002/hbm.24520.CrossRefPubMedPubMedCentral

63.

Doi T, Blumen HM, Verghese J, Shimada H, Makizako H, Tsutsumimoto K, et al. Gray matter volume and dual-task gait performance in mild cognitive impairment. Brain Imaging Behav. 2017;11(3):887–98. doi:https://doi.org/10.1007/s11682-016-9562-1.CrossRefPubMedPubMedCentral

64.

Johnson JA, Strafella AP, Zatorre RJ. The role of the dorsolateral prefrontal cortex in bimodal divided attention: two transcranial magnetic stimulation studies. J Cogn Neurosci. 2007;19(6):907–20. doi:https://doi.org/10.1162/jocn.2007.19.6.907.CrossRefPubMed

65.

Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron. 2008;58(3):306–24. doi:https://doi.org/10.1016/j.neuron.2008.04.017.CrossRefPubMedPubMedCentral

Title: Association between P300 parameters and cognitive function in people with diabetic neuropathy
Authors: Sarah Parveen
Majumi M. Noohu
Publication date: 05-11-2022
Publisher: Springer International Publishing
Keywords: Diabetic Neuropathy
Diabetic Neuropathy
Diabetes
Type 2 Diabetes
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2023
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-022-01148-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Hybrid adaptive deep learning classifier for early detection of diabetic retinopathy using optimal feature extraction and classification

A pre-clinical study to investigate the anti-diabetic potential of p-propoxybenzoic acid as a multi-target inhibitor in streptozotocin-nicotinamide induced type-2 diabetic rats

COVID-19 anti-vaccine attitude and hesitancy

Effect of using mobile phone communication on dietary management of Type 2 Diabetes Mellitus patients in Kenya

Correction to: Evaluation of curcumin effect on Il6, Sirt1, TNFα and NFkB expression of liver tissues in diabetic mice with STZ

Relationship of cardiovascular risk factors, pericardial fat, and carotid thickness with coronary plaque type in patients with diabetes mellitus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials